Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lomustine + etoposide + cytarabine + melphalan
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Lomustine + etoposide + cytarabine + melphalan (LEAM) is a high-dose chemotherapy conditioning regimen used prior to autologous hematopoietic stem cell transplantation (auto-HSCT) in patients with relapsed or refractory Hodgkin lymphoma and Non-Hodgkin lymphoma. Developed as an alternative to the standard BEAM regimen (which contains carmustine instead of lomustine) to mitigate carmustine shortages and potential pulmonary toxicities, LEAM consists of four generic cytotoxic chemotherapy agents. Lomustine is an oral nitrosourea that acts as a DNA alkylating agent; etoposide is an inhibitor of topoisomerase II; cytarabine is an antimetabolite that interferes with DNA synthesis; and melphalan is an intravenous alkylating agent. The regimen is typically administered in hospital or transplant center settings to eradicate residual cancer cells and ablate the bone marrow before stem cell rescue.
- Other names
- CCNU, etoposide, cytarabine, and melphalanCCNU, etoposide, cytarabine, melphalanLEAMLEAM protocolLEAM regimenlomustine, etoposide, cytarabine, and melphalanlomustine, etoposide, cytarabine, melphalan
02
Targets
DNADNA polymerase familyTOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on lomustine + etoposide + cytarabine + melphalan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lomustine + etoposide + cytarabine + melphalan.